Dashboard
Manage Tickers

MIRMMirum Pharmaceuticals, Inc.

Nasdaq mirumpharma.com


$ 36.58 $ 0.69 (1.92 %)    

Tuesday, 09-Jul-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 499.83 $ -0.05 (-0.01 %)
DIA $ 392.99 $ -0.52 (-0.13 %)
SPY $ 555.81 $ 0.54 (0.1 %)
TLT $ 92.34 $ -0.41 (-0.44 %)
GLD $ 218.57 $ 0.37 (0.17 %)
$ 36.6
$ 35.60
$ 0.00 x 0
$ 0.00 x 0
$ 35.47 - $ 36.90
$ 23.14 - $ 36.92
561,983
na
1.72B
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-15-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-09-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-09-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-28-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-66-price-target
HC Wainwright & Co. Reiterates Buy on Miru...
07/08/2024 17:54:19

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...

mirum-pharmaceuticals-livmarli-approved-in-the-eu-for-patients-with-pfic-in-patients-3-months-of-age-and-older
Mirum Pharmaceuticals' LIVMARLI Approved I...
07/08/2024 12:38:45

European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older.Approval f...

hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-66-price-target
HC Wainwright & Co. Reiterates Buy on Miru...
06/28/2024 17:26:22

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...

mirum-submits-new-drug-application-to-fda-for-chenodiol-for-treatment-of-ctx
Mirum Submits New Drug Application To FDA ...
06/28/2024 12:36:22

Submission based on the positive Phase 3 RESTORE studyMirum holds orphan designation for chenodiol in CTXPotential to have firs...

stifel-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-66
Stifel Maintains Buy on Mirum Pharmaceutic...
06/20/2024 13:22:57

Stifel analyst Dae Gon Ha maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $48 to $66.

citigroup-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-64
Citigroup Maintains Buy on Mirum Pharmaceu...
06/18/2024 14:43:01

Citigroup analyst David Lebowitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $...

jp-morgan-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-39
JP Morgan Maintains Overweight on Mirum Ph...
06/18/2024 14:09:38

JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target fr...

nvidia-to-rally-around-53-here-are-10-top-analyst-forecasts-for-tuesday
Nvidia To Rally Around 53%? Here Are 10 To...
06/18/2024 13:44:27

morgan-stanley-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-57
Morgan Stanley Maintains Overweight on Mir...
06/18/2024 11:08:58

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price targ...

jmp-securities-maintains-market-outperform-on-mirum-pharmaceuticals-raises-price-target-to-68
JMP Securities Maintains Market Outperform...
06/18/2024 10:53:09

JMP Securities analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises t...

why-ovid-therapeutics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Ovid Therapeutics Shares Are Trading L...
06/17/2024 17:21:47

hc-wainwright--co-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-66
HC Wainwright & Co. Maintains Buy on Mirum...
06/17/2024 17:03:13

HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
06/17/2024 16:31:43

stifel-reiterates-buy-on-mirum-pharmaceuticals-maintains-48-price-target
Stifel Reiterates Buy on Mirum Pharmaceuti...
06/17/2024 16:07:37

Stifel analyst Dae Gon Ha reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $48 price target.

baird-maintains-outperform-on-mirum-pharmaceuticals-raises-price-target-to-39
Baird Maintains Outperform on Mirum Pharma...
06/17/2024 16:04:00

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from...

mirum-pharmaceuticals-highlights-encouraging-data-for-rare-liver-disease-therapy-from-two-mid-stage-studies
Mirum Pharmaceuticals Highlights Encouragi...
06/17/2024 14:53:34

Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis an...

aarons-mirum-pharmaceuticals-primo-water-and-other-big-stocks-moving-higher-on-monday
Aaron's, Mirum Pharmaceuticals, Primo Wate...
06/17/2024 13:59:35

mirums-volixibat-achieves-interim-analyses-in-vantage-pbc-and-vistas-psc-studies-showed-38-point-reduction-from-baseline-and-23-point-placebo-adjusted-reduction-in-primary-endpoint-of-pruritus
Mirum's Volixibat Achieves Interim Analyse...
06/17/2024 12:11:17

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in p...

hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-58-price-target
HC Wainwright & Co. Reiterates Buy on Miru...
06/07/2024 11:10:57

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price ta...

mirum-pharmaceuticals-presents-long-term-data-from-its-livmarli-studies-in-algs-and-pfic-highlighted-at-the-easl-annual-congress-june-5-8-2024-in-milan-italy
Mirum Pharmaceuticals Presents Long-Term D...
06/06/2024 13:32:28

- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome- Lon...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)